LIN vs TARA · P/E 34, rev $18.07B vs $228.8M cap
Linde plc Ordinary Shares (LIN) versus Protara Therapeutics Inc (TARA) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Protara Therapeutics Inc (TARA) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
TARA does not have a complete income-statement cache yet.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. TARA currently screens at market cap $228.8M.
Not investment advice. Open the LIN and TARA stock pages for the full models.
Not investment advice.